PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 235-241

  Burger, Michael C ^a   Brucker, D P ^a   Baumgarten, P ^a   Ronellenfitsch, M W ^a   Wanka, C ^a   Hasselblatt, M ^b   Eccles, M R ^c   Klingebiel, T ^a   Weller, M ^d   Rieger, J ^a   Mittelbronn, M ^a   Steinbach, J P ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Daoy; GDNF; Glioma; Medulloblastoma; PAX2; T98G

Indexed keywords

BIOLOGICAL MARKER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; NEUROGENIN 2; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DLX1; TRANSCRIPTION FACTOR EMX2; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ARTICLE; BRAIN DEVELOPMENT; CANCER CELL CULTURE; CANCER PATIENT; CARCINOGENESIS; CELL LINEAGE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; MEDULLOBLASTOMA; PATHOGENESIS; PAX2 GENE; PAX5 GENE; PAX8 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RHOMBENCEPHALON; TISSUE MICROARRAY;

ANIMALS; ANTIGENS, DIFFERENTIATION; APOPTOSIS REGULATORY PROTEINS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HOMEODOMAIN PROTEINS; MEDULLOBLASTOMA; MICE; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; RNA INTERFERENCE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862891193     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1446     Document Type: Article

References (25)

1. Maulbecker CC and Gruss P: The oncogenic potential of Pax genes. EMBO J 12: 2361-2367, 1993. (Pubitemid 23194186)
2. Stuart ET and Gruss P: PAX: developmental control genes in cell growth and differentiation. Cell Growth Differ 7: 405-412, 1996. (Pubitemid 26360779)
3. Urbanek P, Fetka I, Meisler MH and Busslinger M: Cooperation of Pax2 and Pax5 in midbrain and cerebellum development. Proc Natl Acad Sci USA 94: 5703-5708, 1997. (Pubitemid 27241833)
4. Dressler GR, Wilkinson JE, Rothenpieler UW, Patterson LT, Williams-Simons L and Westphal H: Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature 362: 65-67, 1993. (Pubitemid 23087291)
5. Galili N, Davis RJ, Fredericks WJ, et al: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230-235, 1993. (Pubitemid 23330384)
6. Busslinger M, Klix N, Pfeffer P, Graninger PG and Kozmik Z: Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 93: 6129-6134, 1996. (Pubitemid 26190815)
7. Kroll TG, Sarraf P, Pecciarini L, et al: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289: 1357-1360, 2000. (Pubitemid 30656054)
8. Murer L, Caridi G, Della Vella M, et al: Expression of nuclear transcription factor PAX2 in renal biopsies of juvenile nephronophthisis. Nephron 91: 588-593, 2002. (Pubitemid 34914057)
9. Winyard PJ, Risdon RA, Sams VR, Dressler GR and Woolf AS: The PAX2 tanscription factor is expressed in cystic and hyperproliferative dysplastic epithelia in human kidney malformations. J Clin Invest 98: 451-459, 1996. (Pubitemid 26255745)
10. Gnarra JR and Dressler GR: Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 55: 4092-4098, 1995.
11. Hueber PA, Waters P, Clark P, Eccles M and Goodyer P: PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int 69: 1139-1145, 2006.
12. Torban E, Eccles MR, Favor J and Goodyer PR: PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 157: 833-842, 2000. (Pubitemid 32109376)
13. Muratovska A, Zhou C, He S, Goodyer P and Eccles MR: Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22: 7989-7997, 2003. (Pubitemid 37179944)
14. Stuart ET, Haffner R, Oren M and Gruss P: Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14: 5638-5645, 1995.
15. Steinbach JP, Klumpp A, Wolburg H and Weller M: Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 64: 1575-1578, 2004. (Pubitemid 38428673)
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
17. Mittelbronn M, Capper D, Bunz B, et al: De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol 33: 299-307, 2007. (Pubitemid 46701048)
18. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007. (Pubitemid 47103521)
19. Liao CL, Lee MY, Tyan YS, et al: Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med 7: 37, 2009.
20. Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006. (Pubitemid 43357943)
21. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442, 2002. (Pubitemid 34100955)
22. Remke M, Hielscher T, Northcott PA, et al: Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29: 2717-2723, 2011.
23. Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R and Schafer BW: PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61: 823-826, 2001. (Pubitemid 32174385)
24. Gibson W, Green A, Bullard RS, Eaddy AC and Donald CD: Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Lett 248: 251-261, 2007. (Pubitemid 46330557)
25. Ishii N, Maier D, Merlo A, et al: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479, 1999. (Pubitemid 29316287)